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Abstract
Epidemiological data suggest that pre-eclampsia (PE) is associated with an increased risk of post-delivery metabolic
dysregulation. The aim of the present case–control observational study was to examine the global plasma proteomic
proﬁle 1 year postpartum in women who developed PE during pregnancy (n= 5) compared to controls (n= 5), in
order to identify a novel predictive marker linking PE with long-term metabolic imbalance. Key ﬁndings were veriﬁed
with enzyme-linked immunosorbent assay (ELISA) in a separate cohort (n= 17 women with PE and n= 43 controls).
One hundred and seventy-two proteins were differentially expressed in the PE vs. control groups. Gene ontology
analysis showed that Inﬂammatory|Immune responses, Blood coagulation and Metabolism were signiﬁcantly enriched
terms. CD14, mapping to the inﬂammatory response protein network, was selected for veriﬁcation based on
bibliographic evidence. ELISA measurements showed CD14 to be signiﬁcantly increased 1 year postpartum in women
with PE during pregnancy compared to controls [PE group (median ± SD): 296.5 ± 113.6; control group (median ± SD):
128.9 ± 98.5; Mann–Whitney U test p= 0.0078]. Overall, the identiﬁed proteins could provide insight into the long-term
disease risk among women with PE during pregnancy and highlight the need for their postpartum monitoring. CD14
could be examined in larger cohorts as a predictive marker of insulin resistance and type II diabetes mellitus among
women with PE.
Introduction
Pre-eclampsia (PE) is a relatively common pregnancy
complication, affecting 2–8% of all pregnancies and a
leading cause of perinatal and maternal death. The con-
dition is deﬁned by new onset of hypertension (over 140/
90mmHg, measured on two occasions at least 4–6 h
apart) that ensues after the 20th week of gestation. Other
common clinical manifestations of PE include foetal
growth restriction, signs of maternal organ dysfunction
and de novo proteinuria (over 300mg over 24 h)1.
Initially, pre-eclampsia that occurred during the ﬁrst
pregnancy was considered to have no long-term adverse
effects2. However, emerging epidemiological data suggest
that pre-eclampsia is associated with a 2–4-fold increased
risk of cardiovascular disease3. More speciﬁcally, women
with pre-eclampsia are at risk for chronic hypertension4,
fatal and non-fatal coronary heart disease, venous
thromboembolism and stroke5. With regards to metabolic
complications, evidence is more scarce. A systematic
review and meta-analysis6 showed that PE is indepen-
dently associated with a 2-fold increased risk of type II
diabetes mellitus 1–10 years postpartum.
Plasma proteomics refers to the untargeted analysis of
the global circulating proteome. Shotgun proteomics is
becoming a very important tool in clinical research, as it
can provide valuable insight into the pathophysiology of
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disease but also identify novel disease markers and ther-
apeutic targets7–9. A recently published study by Murphy
et al.10 examined the maternal circulating proteome
6 months postpartum of women with pre-eclampsia (n=
12) compared to controls (n= 12) using label-free quan-
titative proteomics. This study reported the identiﬁcation
of only 126 peptides, exhibiting low coverage of the cir-
culating proteome.
The aim of the present study was to examine the global
plasma proteomic proﬁle 1 year postpartum in women
with pre-eclampsia during pregnancy to identify novel
predictive markers of long-term metabolic dysregulation.
An overview of the study design is presented in Fig. 1a.
Materials and methods
Study participants
Reporting of the present observational study adheres
to the STROBE guidelines11. The study received ethics
approval by the Southampton and South West Hamp-
shire local research ethics committee. Participants were
recruited through poster advertising at the South-
ampton General Hospital and local GP ofﬁces between
February and April 2017. All participants signed
informed consent forms. Females with one child and no
miscarriages, who delivered 1 year prior to the
recruitment date and either developed or did not
develop pre-eclampsia during pregnancy, with normal
weight gain during pregnancy (11–16 kg), normal pre-
pregnancy and 1-year postpartum body mass index
(BMI) (18–25 kg/m2) were included in the study.
Smokers, females with pre-pregnancy or 1-year post-
partum overweight/obesity (BMI > 25 kg/m2), pre-
pregnancy type I or type II diabetes mellitus, pre-
pregnancy hypertension and gestational diabetes were
excluded from the study. Seventy participants were
considered eligible and all were included in the present
case–control observational study (n= 48 controls and
n= 22 women with pre-eclampsia during pregnancy).
The study participants were randomly assigned into two
cohorts: the discovery cohort (n= 5 controls and n= 5
women with pre-eclampsia during pregnancy) and the
veriﬁcation cohort (n= 43 controls and n= 17 women
with pre-eclampsia during pregnancy). Plasma from
women in the discovery cohort was used for the
quantitative proteomics analysis, whereas plasma from
women in the validation cohort was used for the
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Fig. 1 Agnostic Quantitative Proteomics of Non-Depleted Plasma. a Study design. b Principal component analysis of all analysed plasma
proteins. c Volcano plot of mean TMT log 2 ratio (PE vs. control) plotted against the minus log 10(p value) of the one-sample T test for the respective
quantiﬁed proteins.
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targeted enzyme-linked immunosorbent assay (ELISA)
validation of key proteomic ﬁndings.
Clinical data analysis
Clinical data were analysed using Prism (version 7.0a).
All parameters are presented as mean ± standard devia-
tion. An unpaired, two-tailed Student’s T test was applied
to compare the baseline characteristics of participants.
Plasma proteomic analysis
Plasma specimens were subjected to global quantitative
proteomic analysis using our previously published
method12–14. Unprocessed raw ﬁles were submitted to
Proteome Discoverer 1.4 for target decoy search against
the UniProtKB Homo Sapiens database (release date 10
January 2015) using SequestHT. Median normalisation
and log 2 transformation were performed for the reporter
ion quantiﬁcation ratios. A protein was considered dif-
ferentially expressed between the pre-eclampsia vs. con-
trol group when its one-sample, two-sided, T test p value
was ≤0.05 and mean tandem mass tag (TMT) log 2 ratio
was >|0.3|. Only proteins identiﬁed with at least two
unique peptides were further considered for bioinfor-
matics analysis. All mass spectrometry proteomics data
have been deposited to the ProteomeXchange Con-
sortium via the PRIDE partner repository with the dataset
identiﬁer PXD009325.
Principal component analysis and bioinformatics
interrogation
Principal component analysis (PCA) using the reporter
ion ratios of the differentially expressed proteins (DEPs)
in PE vs. control groups was performed using the online
software tool ClustVis (https://biit.cs.ut.ee/clustvis/).
DAVID (Database for Annotation, Visualisation and
Integrated Discovery; https://david.ncifcrf.gov/) and
Ingenuity Pathway Analysis (IPA) (Qiagen, Hilden, Ger-
many) bioinformatics tools were used to identify gene
ontology (GO) terms, pathways and protein networks
signiﬁcantly enriched in the DEPs between PE and control
groups. Signiﬁcance was set at p value ≤ 0.05.
Single-blinded ELISA measurements
For the ELISA validation of key proteomic ﬁndings, we
used a single-blinded design, wherein assignment of par-
ticipants to PE or control group was not available for the
analyst performing the measurements and uncovered by
an independent statistician after the measurements were
completed. The CD14 ELISA Kit (catalogue no. LS-F4460,
Lifespan Biosciences, Seattle, WA, USA) was used as per
the manufacturer’s recommendations. Absorbance was
measured with the GloMax Discover, Promega plate
reader (Thermo Fisher Scientiﬁc, Waltham, MA, USA).
Data were analysed in Prism (version 7.0a). Statistical
analyses of the ELISA measurements were based on the
non-parametric Mann–Whitney U test to assess differ-
ences between the PE and control groups. Signiﬁcance
was set at p < 0.05. A receiver-operating characteristic
(ROC) curve for CD14 using the ELISA measurements
was generated using Prism (version 7.0a). The area under
the curve (AUC), standard error (SE), 95% conﬁdence
intervals (CIs) and p value were also calculated by Prism
(version 7.0a).
Results
For the discovery cohort, PE and control (C) groups
were similar with regards to age (PE: 36.3 ± 5.6; C: 34.0 ±
4.0; p= 0.47), pre-pregnancy BMI (PE: 22.0 ± 2.6; C:
22.5 ± 2.5; p= 0.49), 1-year postpartum BMI (PE: 24.2 ±
3.5; C: 27.0 ± 4.9; p= 0.32), 1-year postpartum fasting
glucose levels (PE: 4.5 ± 0.8; C: 4.0 ± 0.9; p= 0.20), 1-year
postpartum fasting insulin levels (PE: 5.0 ± 2.5; C: 4.5 ±
2.0; p= 0.31), weight gain during pregnancy (PE: 13.0 ±
2.1; C: 13.5 ± 2.5; p= 0.72), gravidity (PE: 1 ± 0; C: 1 ± 0;
p= 1.0) and parity (PE: 1 ± 0; C: 1 ± 0; p= 1.0). Similarly,
for the veriﬁcation cohort PE and control (C) groups were
similar with regards to age (PE: 35.4 ± 5.8; C: 34.9 ± 4.4;
p= 0.58), pre-pregnancy BMI (PE: 23.1 ± 1.8; C: 22.7 ±
2.1; p= 0.63), 1-year postpartum BMI (PE: 24.8 ± 2.6; C:
25.2 ± 4.5; p= 0.79), 1-year postpartum fasting glucose
levels (PE: 4.0 ± 0.8; C: 4.1 ± 1.0; p= 0.75), 1-year post-
partum fasting insulin levels (PE: 5.3 ± 1.9; C: 4.8 ± 2.6;
p= 0.62), weight gain during pregnancy (PE: 14.0 ± 3.1; C:
13.0 ± 5.0; p= 0.35), gravidity (PE: 1 ± 0; C: 1 ± 0; p= 1.0)
and parity (PE: 1 ± 0; C: 1 ± 0; p= 1.0).
The plasma proteomic study resulted in the identiﬁca-
tion of 1421 unique proteins (peptide false discovery rate
p < 0.05). PCA of all quantiﬁed proteins showed that
women with pre-eclampsia during pregnancy had a dis-
tinct plasma proteomic proﬁle 1 year after delivery com-
pared to the control group [data variability incorporated
by principal components (PCs) 1, 2 and 3 (%) were 23.1,
13.9 and 12.9, respectively] (Fig. 1b). A volcano plot of the
analysed proteome [mean TMT log 2 ratio (PE vs. con-
trol) plotted against the minus log10 p value of the one-
sample T test per protein] is presented in Fig. 1c.
In total, 172 proteins were differentially expressed in the
PE vs. control groups. The canonical pathway analysis
feature of IPA showed that the intrinsic prothrombin
activation pathway was signiﬁcantly induced in the PE
group compared to control (Fig. 2a). GO analysis using
DAVID showed that terms related to Blood coagulation,
Inﬂammatory|Immune responses and Metabolism were
signiﬁcantly enriched in the DEPs (Fig. 2b). DEPs map-
ping to these GO term groups are presented in heatmap
format in Fig. 2c. IPA showed that the inﬂammatory
response protein network was enriched in the DEPs
(Fig. 2d). The monocyte differentiation antigen CD14,
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which mapped onto the inﬂammatory response network,
was found to be up-regulated 1 year after delivery in
women with PE compared to controls [mean TMT log 2
ratio (SD)= 0.3 (4.1)] and this trend was veriﬁed with
ELISA in an independent cohort [PE group (median ±
SD): 296.5 ± 113.6; control group (median ± SD): 128.9 ±
98.5; Mann–Whitney U test p= 0.0078] (Fig. 2e). To
determine the predictive power of CD14 to distinguish
between women with pre-eclampsia vs. controls 1 year
postpartum, an ROC curve was generated (Fig. 2f). The
AUC measure was 0.72, with an SE of 0.08, 95% CI from
0.57 to 0.87 and a p value of 0.008. When the cutoff of
plasma CD14 concentration was set at 167.6 ng/mL, the
sensitivity was 69.77% (95% CI: 54.89–81.40) and the
speciﬁcity was 70.59% (95% CI: 46.87–86.72).
Discussion
This study reports the most comprehensive to date
plasma proteomics proﬁling of women with pre-eclampsia
compared to controls 1 year postpartum. The study
results show that Inﬂammation|Immune response, blood
coagulation and metabolism were dysregulated processes
1 year after delivery in women with pre-eclampsia during
pregnancy.
An observational case–control study with a mean
follow-up of 3 years that included ~13,000 women in the
pre-eclamspia group and 280,000 women in the control
group identiﬁed a small but signiﬁcantly increased risk of
venous thromboembolism as a result of pre-eclampsia
during pregnancy15. In our study, the identiﬁcation of the
induction of the intrinsic prothrombin activation pathway
(Fig. 2a) and blood coagulation as signiﬁcantly enriched
GO term (Fig. 2b) served as positive controls for the
validity of our global plasma proteomic proﬁling.
The monocyte differentiation antigen CD14 (CD14)
mapped to the immune/inﬂammatory response GO term
(Fig. 2c) and the inﬂammatory response protein interac-
tion network (Fig. 2d). Based on this evidence and bib-
liographic research, CD14 was selected for further ELISA
veriﬁcation as a potential marker linking PE with long-
term metabolic dysregulation. CD14, a 55-kDa protein
expressed found in membrane-anchored and soluble
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Fig. 2 Bioinformatics Interpretation and ELISA Veriﬁcation. a Pathway analysis with IPA showed that the intrinsic prothrombin activation
pathway was signiﬁcantly induced in the PE group compared to control. b Gene ontology analysis using DAVID showed that terms related to Blood
coagulation, Inﬂammatory|Immune responses and Metabolism were signiﬁcantly enriched in the differentially expressed proteins (DEPs). c DEPs
mapping to these gene ontology term groups in heatmap format. d Direct protein interaction network associated with inﬂammatory response. CD14
mapped onto this network. e CD14 was found to be up-regulated 1 year after delivery in women with PE compared to controls with quantitative
proteomics. This trend was veriﬁed with ELISA in an independent veriﬁcation cohort. f ROC curve using the ELISA measurements of CD14 plasma
levels 1 year postpartum. The AUC measure was 0.72, with an SE of 0.08, 95% CI from 0.57 to 0.87, and a p value of 0.008. When the cut-off of plasma
CD14 concentration was set at 167.6 ng/mL, the sensitivity was 69.77% (95% CI: 54.89–81.40) and speciﬁcity 70.59% (95% CI: 46.87–86.72).
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serum protein forms, is a co-receptor for bacterial lipo-
polysaccharide and mediator of the inﬂammatory
response. Furthermore, CD14 has been shown to parti-
cipate in adipose tissue-related chronic inﬂammation, and
the eventual development of insulin resistance as a result
of chronic inﬂammatory signals16. Our plasma proteomic
results showed that women with pre-eclampsia 1 year
after delivery have higher CD14 levels compared to con-
trols and this ﬁnding was veriﬁed using ELISA in an
independent cohort (Fig. 2e). The ROC curve analysis
showed a moderate level of success (71.96% AUC, 95% CI:
56.95–86.96) for using CD14 plasma levels to distinguish
women with pre-eclampsia vs. controls 1 year post-
partum. This increase in circulating CD14 levels could
reﬂect a pro-inﬂammatory status of women with pre-
eclampsia after delivery and possible underlying risk of
developing insulin resistance and type II diabetes mellitus.
The main drawback of the present study is its small
sample size. Due to the limited sample size, we expect
some of the identiﬁed DEPs to be false positives. In
conclusion, the present plasma proteomics proﬁling 1
year postpartum of women with PE vs. controls provides
insight into the dysregulated cardiometabolic proﬁle in
this population group and highlights the need for their
long-term health monitoring. The clinical importance of
CD14 as a predictive marker of insulin resistance and type
2 diabetes mellitus among women with PE during preg-
nancy should be further examined in large multi-centre
cohorts.
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